Dyne Therapeutics Names Editas Medicine's Lucera as CFO

Dow Jones03-20 21:14

By Kelly Cloonan

Dyne Therapeutics named Erick Lucera as chief financial officer, effective March 31, adding an industry veteran of more than three decades to the biotechnology company.

Lucera, 57 years old, joins Dyne, a clinical-stage muscle disease company, from Editas Medicine, where he has served as CFO since May 2023, Dyne said Thursday. He has also held the top finance jobs at Aveo Pharmaceuticals and Valeritas Holdings.

Lucera will receive an annual base salary of $520,000 and will be eligible for an annual incentive bonus of up to 40% of his annualized base salary for each fiscal year, according to a filing with the Securities and Exchange Commission.

Editas promoted Amy Parison, senior vice president of finance, to succeed Lucera as CFO, effective March 28.

Parison, 39, will receive an annual base salary of $415,000 and will be eligible for an annual target bonus equal to 40% of her base salary.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

March 20, 2025 17:14 ET (21:14 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2521494406?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-21 05:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2521494406","market":"sh","top_or_hot":-1,"title":"Dyne Therapeutics Names Editas Medicine's Lucera as CFO","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre>\n \n</pre>\n<p>\n  Dyne <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> named Erick Lucera as chief financial officer, effective March 31, adding an industry veteran of more than three decades to the biotechnology company. \n</p>\n<p>\n  Lucera, 57 years old, joins Dyne, a clinical-stage muscle disease company, from Editas Medicine, where he has served as CFO since May 2023, Dyne said Thursday. He has also held the top finance jobs at Aveo Pharmaceuticals and Valeritas Holdings. \n</p>\n<p>\n  Lucera will receive an annual base salary of $520,000 and will be eligible for an annual incentive bonus of up to 40% of his annualized base salary for each fiscal year, according to a filing with the Securities and Exchange Commission. \n</p>\n<p>\n  Editas promoted Amy Parison, senior vice president of finance, to succeed Lucera as CFO, effective March 28. \n</p>\n<p>\n  Parison, 39, will receive an annual base salary of $415,000 and will be eligible for an annual target bonus equal to 40% of her base salary. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 20, 2025 17:14 ET (21:14 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dyne Therapeutics Names Editas Medicine's Lucera as CFO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDyne Therapeutics Names Editas Medicine's Lucera as CFO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-03-21 05:14</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre>\n \n</pre>\n<p>\n  Dyne <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> named Erick Lucera as chief financial officer, effective March 31, adding an industry veteran of more than three decades to the biotechnology company. \n</p>\n<p>\n  Lucera, 57 years old, joins Dyne, a clinical-stage muscle disease company, from Editas Medicine, where he has served as CFO since May 2023, Dyne said Thursday. He has also held the top finance jobs at Aveo Pharmaceuticals and Valeritas Holdings. \n</p>\n<p>\n  Lucera will receive an annual base salary of $520,000 and will be eligible for an annual incentive bonus of up to 40% of his annualized base salary for each fiscal year, according to a filing with the Securities and Exchange Commission. \n</p>\n<p>\n  Editas promoted Amy Parison, senior vice president of finance, to succeed Lucera as CFO, effective March 28. \n</p>\n<p>\n  Parison, 39, will receive an annual base salary of $415,000 and will be eligible for an annual target bonus equal to 40% of her base salary. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 20, 2025 17:14 ET (21:14 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4556","symbol_name":"基因编辑","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2521494406","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2521494406","pubTimestamp":1742505240,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Dyne Therapeutics named Erick Lucera as chief financial officer, effective March 31, adding an industry veteran of more than three decades to the biotechnology company.Lucera, 57 years old, joins Dyne, a clinical-stage muscle disease company, from Editas Medicine, where he has served as CFO since May 2023, Dyne said Thursday. He has also held the top finance jobs at Aveo Pharmaceuticals and Valeritas Holdings.Lucera will receive an annual base salary of $520,000 and will be eligible for an annual incentive bonus of up to 40% of his annualized base salary for each fiscal year, according to a filing with the Securities and Exchange Commission.Editas promoted Amy Parison, senior vice president of finance, to succeed Lucera as CFO, effective March 28.Parison, 39, will receive an annual base salary of $415,000 and will be eligible for an annual target bonus equal to 40% of her base salary.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4556":"基因编辑","DYN":"戴纳基","BK4585":"ETF&股票定投概念","EDIT":"Editas Medicine, Inc.","BK4139":"生物科技","BK4505":"高瓴资本持仓","BK4588":"碎股","LENZ":"Therapeutics"},"translate_title":"达因治疗公司任命Editas Medicine的Lucera为首席财务官","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DYN":1,"EDIT":1,"LENZ":1},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Dyne Therapeutics named Erick Lucera as chief financial officer, effective March 31, adding an industry veteran of more than three decades to the biotechnology company. \n\n\n  Lucera, 57 years old, joins Dyne, a clinical-stage muscle disease company, from Editas Medicine, where he has served as CFO since May 2023, Dyne said Thursday. He has also held the top finance jobs at Aveo Pharmaceuticals and Valeritas Holdings. \n\n\n  Lucera will receive an annual base salary of $520,000 and will be eligible for an annual incentive bonus of up to 40% of his annualized base salary for each fiscal year, according to a filing with the Securities and Exchange Commission. \n\n\n  Editas promoted Amy Parison, senior vice president of finance, to succeed Lucera as CFO, effective March 28. \n\n\n  Parison, 39, will receive an annual base salary of $415,000 and will be eligible for an annual target bonus equal to 40% of her base salary. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 20, 2025 17:14 ET (21:14 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2521494406"}